Full-Life Technologies announced US$150 million in financing to advance multiple clinical stage assets and manufacturing capacity, with the equity split not detailed in the headline.
- Amount
- $150M
- Announced
- 18 May 2026
- Lead
- Vivo Capital
- Other investors
- SK Biopharmaceuticals Co., Ltd., Chengwei Capital, HSG, Junson Capital, Plaisance, Yunion, Sky9 Capital, TSG Capital
- Use of funds
- Advancing clinical stage assets and starting GMP-grade 225Ac manufacturing at Belgium facility.
- Total raised
- $350M to date
- Checked
- Amount and date checked against the press source